Sonal S Chaugule, MS
Education and Fellowships
- Centre For Sight Eye Hospital, Hyderabad
- New York Eye Cancer Center, New York
Consultant- Ophthalmic Plastic Surgeon, Orbit and Ocular Oncology, PBMA's H V Desai Eye Hospital, Pune, India
Fellow, Ocular Tumors, Orbital Diseases and Ophthalmic Radiotherapy, New York Eye Cancer Center, New York, USA
Fellow, Ophthalmic Plastic Surgery and Ocular Oncology, Centre For Sight Eye Hospital, Hyderabad, india
Dr Sonal S. Chaugule is a consultant ophthalmic plastic surgeon, orbit and ocular oncologist working in PBMA’s H V Desai Eye Hospital, Pune. She has completed her fellowship in ocular tumors, orbital diseases and ophthalmic radiation therapy at The New York Eye Cancer Center, New York, USA (2016-17) and her fellowship in ophthalmic plastic Surgery and ocular oncology from Centre For Sight Super-Specialty Eye Hospital, Hyderabad (2015-16). She graduated with M.B.B.S. from Seth G. S. Medical College and K.E.M. Hospital, Mumbai in 2010 and then received her post-graduate training in Ophthalmology (M.S.) at the Govt. Medical College and Hospital, Aurangabad, where she was ranked 3rd in Maharashtra University of Health Sciences (M.U.H.S.) in 2013. Her areas of specialty include management and clinical research in intraocular tumors with special interest in retinoblastoma and uveal melanoma, ocular surface, eyelid and orbital tumors as well as functional ophthalmic plastic surgery and diseases of lacrimal apparatus. She has presented many papers at various national and international conferences where her work has been well appreciated. She was awarded the prestigious ‘Ophthalmic Hero of India’ award for her international accolades at the 75th All India Ophthalmology Conference (AIOC) in 2017. She has been a recipient of Tano Yusuf travel grant for young ophthalmologists by Annual Asia-Pacific Association of Ophthalmology (APAO) Conference in 2016 as well as Eye Cancer Foundation (ECF) travel grant for presentations at International Society of Ocular Oncology (ISOO) meetings in Paris (2015) and Sydney (2017).
Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
PURPOSE: The purpose of this study is to report on the efficacy and safety of topical chemotherapy alone for giant ocular surface squamous neoplasia (OSSN). CONCLUSION: Topical chemotherapy was a safe and effective treatment, inducing complete regression in all cases of giant OSSN in this series. There were no sight-limiting complications.
Regression Patterns of Iris Melanoma after Palladium-103 (103 Pd) Plaque Brachytherapy
Purpose To evaluate the patterns of regression of iris melanoma after treatment with palladium-103 (103Pd) plaque brachytherapy. Conclusions The most common findings related to iris melanoma regression after 103Pd plaque brachytherapy included decreased intrinsic tumor vascularity, increased tumor pigmentation, and decreased tumor thickness with synchronous increase in internal ultrasonographic reflectivity. No irreversible sight-limiting complications were noted.
Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab
Background/aims To evaluate the effect of adjuvant intravitreal triamcinolone acetonide (ITA) for radiation maculopathy (RM) recalcitrant to high-dose bevacizumab in patients with choroidal melanoma after plaque radiotherapy Conclusion Intravitreal triamcinolone can be added to preserve vision and decrease macular oedema in patients with RM recalcitrant to high-dose anti-vascular endothelial growth factor agents.
Orbital Alveolar Soft Part Sarcoma
Picture and perspective
The Eye Cancer Network is supported by The Eye Cancer Foundation.
Help support eye cancer research and education now »